Wire flash
Sunshine Noah and Wangao Pharma Partner on ABA001, with 50M Yuan Investment
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Sunshine Novo (Sunshine Nuohe) announced a partnership with Jiangsu Wanguo Pharmaceutical Co., Ltd. to jointly develop the ABA001 project, signing a cooperation agreement. Under the terms, Wanguo Pharmaceutical will invest 50 million yuan (approximately $7 million) in this phase, with funds allocated exclusively for domestic clinical trials, research optimization, regulatory filing, compliance operations, and other project-related expenses. The ABA001 drug candidate is currently in Phase I clinical trials. The announcement was made via a stock market live feed on Stockstar, a Chinese financial news platform. The partnership represents a significant financial commitment to advance the development of ABA001 through early-stage clinical testing and regulatory processes in China.
Source report
Sun-Novo has announced that it has entered into a cooperation agreement with Jiangsu Wangao Pharmaceutical Co., Ltd. to jointly develop the ABA001 project, and has signed the ABA001 Project Cooperative Development Agreement.
According to the agreement, Wangao Pharmaceutical will invest RMB 50 million in the current phase. The entire investment will be allocated to domestic clinical trials, research and development optimization, regulatory filing, compliance operations, and other direct project-related expenditures for the product covered under the agreement.
ABA001 is currently in Phase I clinical trials.
Source
证券之星-股市直击Eastern
Part of this Story
Sunshine Noah licenses hypertension siRNA drug ABA001 to Wangao Pharma for 50 million yuan